H. Christian Fibiger, PhD, served as chief scientific officer for Biovail Laboratories International (now Valeant), and as vice president and global head of neuroscience at Amgen. He was responsible for Amgen’s worldwide neuroscience discovery efforts, ranging from early exploratory research through clinical candidate selection. Before joining Amgen, Dr. Fibiger served as vice president of Neuroscience Discovery Research and Clinical Investigation, and LRL Europe at Eli Lilly and Company. Before moving to Lilly in 1998, Dr. Fibiger served as professor and head of the Division of Neurological Sciences and chair of the University Graduate Program in Neuroscience at the University of British Columbia in Vancouver.
Dr. Fibiger has made numerous contributions to neuroscience research and, during his academic career, was among the top 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a fellow of the American College of Neuropsychopharmacology and serves on the editorial boards of several journals in the field of neuroscience and has been coeditor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology.
Dr. Fibiger holds a BSc in chemistry and psychology from the University of Victoria, British Columbia, and a PhD in psychopharmacology from Princeton University.